ARVN — Arvinas, Inc.

Summary of Arvinas (ARVN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $9.5 million, a significant decrease from $59.2 million in Q4 2024, primarily due to a $40.3 million drop in revenue from the Novartis license agreement.
• Full Year Revenue: $262.6 million, slightly down from $263.4 million in 2024.
• Cash Position: $85 million in cash, cash equivalents, and marketable securities at the end of Q4 2025, down from over $1 billion at the end of 2024.
• Expenses:
  • General and Administrative (G&A) expenses were $23 million in Q4 2025, down from $34.1 million in Q4 2024.
  • Research and Development (R&D) expenses were $61.1 million in Q4 2025, down from $83.3 million in Q4 2024.
• Stock Repurchase: Approximately $91.9 million of stock repurchased, program now suspended.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Arvinas is focusing on four ongoing clinical trials across oncology and neurology, including the first-in-human trial of ARV-027, a polyQ AR degrader.
• Key Programs:
  • ARV-102: LRRK2 degrader for Parkinson's disease, with data accepted for presentation at the Alzheimer's and Parkinson's Diseases Conference.
  • ARV-806: KRAS G12D PROTAC, with faster-than-expected enrollment and data expected in 2026.
  • ARV-393: BCL6 degrader showing early responses in lymphoma patients, with data to be shared in 2026.
  • ARV-027: Targeting spinal and bulbar muscular atrophy (SBMA), recently initiated Phase 1 trial.
• Partnerships: Ongoing discussions with potential partners for vepdegestrant's commercialization, aiming for an agreement by the June 5 PDUFA date.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipation of multiple data readouts and clinical advancements across the pipeline, with a focus on differentiated treatments.
• Cash Runway: Guidance maintained for cash to last into 2028, allowing for continued investment in key programs.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in Q4 revenue raises concerns about financial stability and reliance on licensing agreements.
• Cash Burn: The substantial decrease in cash reserves from the previous year may limit operational flexibility.
• Competitive Landscape: High competition in the oncology space, particularly for ARV-806, where differentiation will be crucial to success.
• Regulatory Risks: Potential delays or challenges in obtaining regulatory feedback could impact timelines for clinical trials, especially for ARV-102 in PSP.

5. Notable Q&A Insights

• Differentiation Strategy: Management emphasized the importance of demonstrating clear differentiation for each program, with specific data points expected throughout 2026.
• Regulatory Feedback: Seeking guidance from regulatory authorities on the development strategy for both PSP and Parkinson's disease, with a focus on patient selection and endpoint strategies.
• Safety Monitoring: Acknowledgment of the need for rigorous safety monitoring in LRRK2 studies, particularly concerning lung biology.
• Interest in Vepdegestrant: Positive sentiment regarding Roche's recent data, which may enhance interest in vepdegestrant's potential.

Overall, Arvinas is navigating a pivotal period with significant clinical advancements and a focus on maintaining a strong financial position while addressing competitive pressures and regulatory challenges.